1 2 3 Higa GM, Abraham J (tháng 9 năm 2007). “Lapatinib in the treatment of breast cancer”. Expert Review of Anticancer Therapy (log in required) |format= cần |url= (trợ giúp). Future Drugs. 7 (9): 1183–92. doi:10.1586/14737140.7.9.1183. PMID17892419.
↑ Pazdur, Richard (ngày 14 tháng 1 năm 2011). “FDA Approval for Lapatinib Ditosylate”. Womens Health (Lond Engl). Cancer.gov. 6 (2): 173. doi:10.2217/whe.10.11. PMID20187722.
↑ Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, và đồng nghiệp (2004). “A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells”. Cancer Research. 64 (18): 6652–9. doi:10.1158/0008-5472.CAN-04-1168. PMID15374980.
↑ Nelson MH, Dolder CR (tháng 2 năm 2006). “Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors”. Ann Pharmacother. 40 (2): 261–9. doi:10.1345/aph.1G387. PMID16418322.
↑ Burris HA, Hurwitz HI, Dees EC, và đồng nghiệp (tháng 8 năm 2005). “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas”. J. Clin. Oncol. 23 (23): 5305–13. doi:10.1200/JCO.2005.16.584. PMID15955900.
↑ Sonnenblick A et al. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.J Natl Cancer Inst. 2016 Apr
